Gelonghui, December 23 | Eli Lilly and Co (LLY.US) pre-market rose 2.12% to reach $784. In the news, on Friday (December 20), the USA Food and Drug Administration (FDA) approved Eli Lilly and Co's weight loss drug Zepbound for the treatment of obstructive sleep apnea (OSA), making it the first approved drug to directly treat this common sleep disorder. Analysts predict that by 2030, the annual sales of the global weight loss pharmaceutical market will exceed 100 billion dollars. (Gelonghui)
美股异动丨礼来盘前涨超2% Zepbound获FDA批准
U.S. stocks are active | Eli Lilly and Co rises over 2% in pre-market as Zepbound receives FDA approval.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated